Clinical Trials
9 trialsNCT02465060 2026-06-03
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06390826 2026-05-28
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05043090 2026-05-22
SAMETA
AstraZeneca
Phase 3 Active not recruiting
NCT05208047 2026-05-22
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc.
Phase 3 Active not recruiting
NCT03768063 2026-04-28
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03091192 2026-04-14
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
NCT01396408 2026-03-27
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT03463460 2026-03-23
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT02068586 2026-03-16
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Thomas Jefferson University
Phase 2 Active not recruiting